Urinary tract infection

Laboratory Economics Issues Market Research Report on the U.S. Clinical Laboratory Testing Market

Retrieved on: 
Wednesday, January 3, 2024
UnitedHealth Group, Microbiology, Growth, Cigna, Urinary tract infection, Medicare, Economics, PCR, Pharmaceutical industry

POUGHKEEPSIE, N.Y., Jan. 3, 2024 /PRNewswire-PRWeb/ -- Laboratory Economics has just released The U.S. Clinical Laboratory Industry: Forecast & Trends 2023-2025. With this special report, you can tap into 100+ pages of proprietary market research that reveals critical data and information about key business trends affecting the U.S. laboratory testing market.

Key Points: 
  • POUGHKEEPSIE, N.Y., Jan. 3, 2024 /PRNewswire-PRWeb/ -- Laboratory Economics has just released The U.S. Clinical Laboratory Industry: Forecast & Trends 2023-2025.
  • With this special report, you can tap into 100+ pages of proprietary market research that reveals critical data and information about key business trends affecting the U.S. laboratory testing market.
  • The report reveals that the U.S. laboratory testing market represented an estimated $125 billion of revenue in 2023 with a long-term annual growth rate of 3-4%.
  • The U.S. laboratory testing market faces multiple challenges, including post-pandemic employee wage inflation, greater utilization management and claims denials by private payers, and persistent reimbursement pressure.

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Retrieved on: 
Tuesday, January 2, 2024
Patient, MDR, Sale, Physician, FDA, Tebipenem, Infection, Pyelonephritis, Therapy, HBR, GSK, Spero, Urinary tract infection, AP, Pharmaceutical industry

Spero is entitled to receive $95 million in development milestone payments from GSK, which is payable in four equal installments over two years.

Key Points: 
  • Spero is entitled to receive $95 million in development milestone payments from GSK, which is payable in four equal installments over two years.
  • “First patient visit, in the PIVOT-PO Phase 3 clinical trial, is an important milestone in our tebipenem HBr program,” said Sath Shukla, President and CEO of Spero Therapeutics.
  • "We are developing Tebipenem HBr to potentially be the first oral broad-spectrum carbapenem in the U.S. for use in patients with cUTI.
  • The primary efficacy endpoint will be overall response (composite of clinical cure plus microbiological eradication) at the test-of-cure visit.

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Atmosphere, Urine, Medical Subject Headings, Marketing, Sinusitis, Agency, Pharyngitis, INN, Lower respiratory tract infection, Constipation, Infection, ATC, Pain, Blood, International, Chronic obstructive pulmonary disease, Cough, Bromide, Common, Headache, Nose, Language, Brain, FEV1, Periodic breathing, Mouth, Inhalation, Gestational sac, Heart, Inflammation, B cell, European Medicines Agency, Xerostomia, Select, Patient, Urinary tract infection, Safety, Anatomy, Muscarinic acetylcholine receptor, Throat, IIA, Umeclidinium bromide, Medical device

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Atmosphere, Urine, Medical Subject Headings, Marketing, Sinusitis, Agency, Pharyngitis, INN, Lower respiratory tract infection, Constipation, Infection, ATC, Pain, COPD, Blood, International, Chronic obstructive pulmonary disease, Bromide, Common, Headache, Nose, Cough, Language, Brain, FEV1, Periodic breathing, Mouth, Inhalation, Gestational sac, Heart, Inflammation, Wheeze, B cell, European Medicines Agency, Xerostomia, Select, Patient, Urinary tract infection, Safety, Anatomy, Muscarinic acetylcholine receptor, Throat, IIA, Umeclidinium bromide, Medical device

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Zytiga, abiraterone, Date of authorisation: 05/09/2011, Revision: 27, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, Prednisolone, European Commission, Liver, Agency, Survival, CYP17, INN, Woman, Docetaxel, Fracture, ATC, Male, Hormone, Hypersensitivity, International, Cough, Man, European, Prednisone, Disease, Language, Prostate cancer, Cerebral edema, Eating, Castration, Cancer, Urinary tract infection, Neoplasm, Testosterone, Prostate, Abiraterone acetate, European Medicines Agency, Food, Tablet, Growth, Select, Anatomy, Medicine, IIA, Hypokalemia

Human medicines European public assessment report (EPAR): Zytiga, abiraterone, Date of authorisation: 05/09/2011, Revision: 27, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zytiga, abiraterone, Date of authorisation: 05/09/2011, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Urine, Medical Subject Headings, Diarrhea, Awareness, Marketing, Basiliximab, European Commission, INN, Leukopenia, Risk, Post-transplant lymphoproliferative disorder, Kidney transplantation, Infection, MPA, ATC, Pneumonia, Urinary tract infection, International, Gastroenteritis, Cytomegalovirus, Mycophenolic acid, Language, Pyelonephritis, Ciclosporin, CD86, Cancer, Basal-cell carcinoma, Transplant, Select, Committee, Patient, Human, Dehydration, Risk management, Anatomy, Medicine, Anemia, Vomiting, IIA, CHMP, CD80, Rejection, Dentistry

Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Date of authorisation: 18/02/2019, Revision: 6, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Marketing, Protein, Agency, Pharyngitis, INN, ATC, Urinary tract infection, International, Cough, Cystic fibrosis, Sore throat, Ageing, Language, Literature, Pseudomonas aeruginosa, Catherine Disher, Lower respiratory tract infection, European Medicines Agency, Infection, Fibrosis, Select, Patient, Bacteria, Anatomy, IIA, Periodic breathing, Medical device

Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Date of authorisation: 18/02/2019, Revision: 6, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Date of authorisation: 18/02/2019, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Fetcroja, cefiderocol, Date of authorisation: 23/04/2020, Revision: 8, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Urine, Medical Subject Headings, Diarrhea, Marketing, Agency, INN, Infection, Allergy, ATC, Carbapenem, International, Cough, Nausea, Language, Urinary tract infection, European Medicines Agency, Cilastatin, Bloodstream infections, Imipenem, Select, Patient, Iron, Bacteria, Anatomy, Penicillin, Vomiting, IIA, Gram-negative bacteria, Medical device

Human medicines European public assessment report (EPAR): Fetcroja, cefiderocol, Date of authorisation: 23/04/2020, Revision: 8, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Fetcroja, cefiderocol, Date of authorisation: 23/04/2020, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 6, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Urine, Medical Subject Headings, Marketing, Protein, Acetylcholine receptor, Autoantibody, INN, GMG, Immune system, Fatigue, Lower respiratory tract infection, Infection, ATC, Antibody, International, Disease, Nose, Language, Blood, Muscle weakness, Urinary tract infection, Medicine, B cell, Neonatal Fc receptor, European Medicines Agency, Acetylcholine, Select, Patient, Anatomy, IIA, Medical device

Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 6, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, MRI, INN, Risk, Interferon beta-1a, Immune system, Fatigue, Infection, Registry, ATC, Antibody, Gadolinium, Disability, Multiple sclerosis, International, Attack, Spinal cord, Disease, Common, PML, Nose, Headache, Nausea, Brain, Language, Urinary tract infection, Inflammation, Cancer, Nerve, Dizziness, Skin cancer, Allergy, DMT, Death, European Medicines Agency, Nervous system, Select, Carcinoma, Safety, Encephalitis, Anatomy, Arthralgia, Sclerosis, IIA, Magnetic resonance imaging, Medical device

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised